Head-to-Head: which psoriatic arthritis drug works better in daily life?
NCT ID NCT07386717
First seen Feb 04, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This study looked at 70 adults with psoriatic arthritis to compare two types of drugs—upadacitinib and IL-17 inhibitors—in everyday medical practice. Researchers tracked joint and skin symptoms over 24 weeks to see which treatment worked better. The goal is to help doctors and patients choose the right therapy based on real-world results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.